Thrombolytics, anticoagulants, and antiplatelet agents

Stroke

Volumn 37, Issue 2, 2006, Pages 312-313

  Ringleb, Peter A ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE   (Germany)

Author keywords

Anticoagulants; Antihypertensive agents; Thrombolytic therapy

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DESMOTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; WARFARIN; XIMELAGATRAN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; DEVICE; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG EFFICACY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; SHORT SURVEY; STROKE; CEREBROVASCULAR ACCIDENT; METHODOLOGY; REVIEW; RISK; THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; THROMBOLYTIC THERAPY;

EID: 33644852408     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000200560.01068.65     Document Type: Short Survey

References (11)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; for The DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase. Stroke. 2005;36:66-73.
3. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432-1438.
4. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
5. AstraZeneca. AstraZeneca receives action letter from FDA for Exanta® (Ximelagatran). Available at: http://www.astrazeneca.com/pressrelease/3285.aspx. Accessed November 5, 2005.
6. International-Stroke-Trial-Collobarative-Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. The Lancet. 1997;349:1569-1581.
7. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005;36:2415-2420.
8. The Abcicximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo controlled, dose-escalation study. Stroke. 2000;31:601-609.
9. AbESST investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880-890.
10. Centocor I. Centocor, Inc. And Eli Lilly and Company Halt Phase 3 Trial Of Reopro For Stroke. October 28, 2005. Available at: http://biospace.com/ news_story.aspx?StoryID=853&full=1. Accessed November 5, 2005.
11. Goldberg MP (ed). Stroke Trials Directory. Internet Stroke Center web site. ROSIE. January 25, 2005. Available at: http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=462. Accessed November 5, 2005.